500 related articles for article (PubMed ID: 2007937)
41. Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered before 30 weeks' gestation.
Silver RK; Vyskocil C; Solomon SL; Ragin A; Neerhof MG; Farrell EE
Obstet Gynecol; 1996 May; 87(5 Pt 1):683-91. PubMed ID: 8677067
[TBL] [Abstract][Full Text] [Related]
42. Effect of two different early rescue surfactant treatments on mortality in preterm infants with respiratory distress syndrome.
Kadıoğlu Şimşek G; Kanmaz Kutman HG; Canpolat FE; Oğuz ŞS
Clin Respir J; 2020 Mar; 14(3):285-290. PubMed ID: 31814293
[TBL] [Abstract][Full Text] [Related]
43. Animal derived surfactant extract for treatment of respiratory distress syndrome.
Seger N; Soll R
Cochrane Database Syst Rev; 2009 Apr; (2):CD007836. PubMed ID: 19370695
[TBL] [Abstract][Full Text] [Related]
44. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants.
Soll RF
Cochrane Database Syst Rev; 2000; (2):CD001079. PubMed ID: 10796410
[TBL] [Abstract][Full Text] [Related]
45. Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome.
Hoekstra RE; Jackson JC; Myers TF; Frantz ID; Stern ME; Powers WF; Maurer M; Raye JR; Carrier ST; Gunkel JH
Pediatrics; 1991 Jul; 88(1):10-8. PubMed ID: 2057245
[TBL] [Abstract][Full Text] [Related]
46. Prophylaxis of respiratory distress syndrome by treatment with modified porcine surfactant at birth: a multicentre prospective randomized trial.
Bevilacqua G; Parmigiani S; Robertson B
J Perinat Med; 1996; 24(6):609-20. PubMed ID: 9120744
[TBL] [Abstract][Full Text] [Related]
47. Protein-containing synthetic surfactant versus protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndrome.
Pfister RH; Soll R; Wiswell TE
Cochrane Database Syst Rev; 2009 Oct; (4):CD006180. PubMed ID: 19821357
[TBL] [Abstract][Full Text] [Related]
48. Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia.
Bassler D
Neonatology; 2015; 107(4):358-9. PubMed ID: 26044104
[TBL] [Abstract][Full Text] [Related]
49. An observational study of surfactant treatment in infants of 23-30 weeks' gestation: comparison of prophylaxis and early rescue.
Bevilacqua G; Parmigiani S;
J Matern Fetal Neonatal Med; 2003 Sep; 14(3):197-204. PubMed ID: 14694975
[TBL] [Abstract][Full Text] [Related]
50. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome.
Pfister RH; Soll RF; Wiswell T
Cochrane Database Syst Rev; 2007 Jul; (3):CD006069. PubMed ID: 17636826
[TBL] [Abstract][Full Text] [Related]
51. Sustained lung inflation at birth via short binasal prong in very low birth weight preterm infants: A retrospective study.
Buyuktiryaki M; Kanmaz HG; Okur N; Bezirganoglu H; Ozer Bekmez B; Simsek GK; Canpolat FE; Oguz SS; Tayman C
Pediatr Pulmonol; 2018 Oct; 53(10):1407-1413. PubMed ID: 29999603
[TBL] [Abstract][Full Text] [Related]
52. Prophylactic treatment of very premature infants with human surfactant.
Merritt TA; Hallman M; Bloom BT; Berry C; Benirschke K; Sahn D; Key T; Edwards D; Jarvenpaa AL; Pohjavuori M
N Engl J Med; 1986 Sep; 315(13):785-90. PubMed ID: 3528853
[TBL] [Abstract][Full Text] [Related]
53. Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome.
Liechty EA; Donovan E; Purohit D; Gilhooly J; Feldman B; Noguchi A; Denson SE; Sehgal SS; Gross I; Stevens D
Pediatrics; 1991 Jul; 88(1):19-28. PubMed ID: 2057268
[TBL] [Abstract][Full Text] [Related]
54. Early Intratracheal Administration of Corticosteroid and Pulmonary Surfactant for Preventing Bronchopulmonary Dysplasia in Preterm Infants with Neonatal Respiratory Distress Syndrome: A Meta-analysis.
Zhong YY; Li JC; Liu YL; Zhao XB; Male M; Song DK; Bai Y
Curr Med Sci; 2019 Jun; 39(3):493-499. PubMed ID: 31209823
[TBL] [Abstract][Full Text] [Related]
55. Prophylactic versus selective use of surfactant for preventing morbidity and mortality in preterm infants.
Soll RF; Morley CJ
Cochrane Database Syst Rev; 2000; (2):CD000510. PubMed ID: 10796379
[TBL] [Abstract][Full Text] [Related]
56. Use of surfactant for prophylaxis versus rescue treatment of respiratory distress syndrome: experience from an Italian-Bulgarian trial.
Bevilacqua G; Chernev T; Parmigiani S; Iarakova N; Gaioni L; Volante E; Gambini L; Bussolati G
Acta Biomed Ateneo Parmense; 1997; 68 Suppl 1():47-54. PubMed ID: 10021717
[TBL] [Abstract][Full Text] [Related]
57. Improving the prediction of surfactant deficiency in very low-birthweight infants with respiratory distress.
Harker LC; Merritt TA; Edwards DK
J Perinatol; 1992 Jun; 12(2):129-33. PubMed ID: 1522430
[TBL] [Abstract][Full Text] [Related]
58. Cost effects of surfactant therapy for neonatal respiratory distress syndrome.
Phibbs CS; Phibbs RH; Wakeley A; Schlueter MA; Sniderman S; Tooley WH
J Pediatr; 1993 Dec; 123(6):953-62. PubMed ID: 8229530
[TBL] [Abstract][Full Text] [Related]
59. A pilot randomized, controlled trial of later treatment with a peptide-containing, synthetic surfactant for the prevention of bronchopulmonary dysplasia.
Laughon M; Bose C; Moya F; Aschner J; Donn SM; Morabito C; Cummings JJ; Segal R; Guardia C; Liu G;
Pediatrics; 2009 Jan; 123(1):89-96. PubMed ID: 19117865
[TBL] [Abstract][Full Text] [Related]
60. High-versus low-threshold surfactant retreatment for neonatal respiratory distress syndrome.
Kattwinkel J; Bloom BT; Delmore P; Glick C; Brown D; Lopez S; Willett L; Egan EA; Conaway M; Patrie J
Pediatrics; 2000 Aug; 106(2 Pt 1):282-8. PubMed ID: 10920152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
